Revenue
No reported data
Damora Therapeutics, Inc. (DMRA)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
2022
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $26.9M | $6.4M | $23.8M | $48.2M | $38.5M | $24.6M | $19.7M |
| Operating expenses | $210.9M | $22.3M | $39.9M | $61.2M | $52.2M | $33.6M | $39.0M |
| Operating income | −$210.9M | −$22.3M | −$39.9M | −$61.2M | −$52.2M | −$33.6M | $39.0M |
| Net income | −$209.8M | −$21.4M | −$38.3M | −$61.6M | −$51.8M | −$34.8M | −$36.5M |
| Basic EPSper diluted share | $3.98 | -$18.53 | -$36.08 | -$2.43 | -$2.05 | -$7.62 | -$161.82 |
| Diluted EPSper diluted share | $3.98 | -$18.53 | -$36.08 | -$2.43 | -$2.05 | -$7.62 | -$161.82 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 2, 2026Form 4 | Schambye Hans T.Chief Executive Officer | SellCommon Stock | 700 | $21.38 | $15.0K | 4.7K |
| Jan 2, 2026Form 4 | Winslow GarrettGeneral Counsel | SellCommon Stock | 255 | $21.38 | $5.5K | 1.9K |
| Jan 2, 2026Form 4 | Firmani LoriChief Financial Officer | SellCommon Stock | 135 | $21.41 | $2.9K | 931 |
| Jul 3, 2025Form 4 | Schambye Hans T.Chief Executive Officer | SellCommon Stock | 735 | $3.38 | $2.5K | 4.0K |
| Jul 3, 2025Form 4 | Winslow GarrettGeneral Counsel | SellCommon Stock | 260 | $3.39 | $881.40 | 1.4K |